Springhill Fund Asset Management HK Co Ltd Purchases New Holdings in ABIVAX Société Anonyme (NASDAQ:ABVX)

Springhill Fund Asset Management HK Co Ltd purchased a new stake in ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 207,600 shares of the company's stock, valued at approximately $1,520,000. ABIVAX Société Anonyme makes up 2.5% of Springhill Fund Asset Management HK Co Ltd's holdings, making the stock its 16th largest holding. Springhill Fund Asset Management HK Co Ltd owned 0.33% of ABIVAX Société Anonyme as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. abrdn plc boosted its holdings in shares of ABIVAX Société Anonyme by 34.1% in the 4th quarter. abrdn plc now owns 424,181 shares of the company's stock worth $3,105,000 after acquiring an additional 107,750 shares in the last quarter. GAMMA Investing LLC acquired a new position in ABIVAX Société Anonyme in the fourth quarter worth $29,000. Point72 Asset Management L.P. grew its holdings in shares of ABIVAX Société Anonyme by 28.2% during the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company's stock worth $6,254,000 after purchasing an additional 119,300 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of ABIVAX Société Anonyme by 10.7% in the fourth quarter. Franklin Resources Inc. now owns 1,466,062 shares of the company's stock valued at $10,732,000 after buying an additional 141,710 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock valued at $150,000 after buying an additional 5,900 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company's stock.

Analyst Ratings Changes

Several research firms have weighed in on ABVX. Morgan Stanley restated an "equal weight" rating and issued a $12.00 price objective on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th. JMP Securities reaffirmed a "market outperform" rating and set a $33.00 price objective on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $38.00.

ABIVAX Société Anonyme Price Performance

ABVX traded up $0.13 during trading on Friday, reaching $5.72. 11,745 shares of the company's stock were exchanged, compared to its average volume of 127,477. The company's fifty day moving average price is $6.71 and its 200-day moving average price is $7.92. ABIVAX Société Anonyme has a fifty-two week low of $4.77 and a fifty-two week high of $16.63.

ABIVAX Société Anonyme Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.